Heart Failure Risk Reduction in Diabetes: What the Practicing Endocrinologist Should Know

Download All
Join the experts at this live webinar as they discuss leveraging the cardioprotective effects of SGLT2 inhibitors to reduce heart failure risk in your patients with type 2 diabetes.
Jennifer B. Green, MD
Mikhail N. Kosiborod, MD

Downloadable Slideset

Expert faculty discuss the latest data on using SGLT2 inhibitors to reduce HF risk in patients with T2D

Jennifer B. Green, MD Mikhail N. Kosiborod, MD Released: June 7, 2021
Provided by the Endocrine Society

For questions about content or obtaining CME credit, please contact the Endocrine Society at www.education.endocrine.org/contact.

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.